Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials

BACKGROUND: Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inadequate efficacy or poor tolerability in some individuals. Ubrogepant is an oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Singh, Rashmi B. Halker, Revicki, Dennis A., Zhao, Sihui, Shewale, Anand R., Lateiner, Jordan E., Dodick, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036751/
https://www.ncbi.nlm.nih.gov/pubmed/35468729
http://dx.doi.org/10.1186/s10194-022-01419-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036751/
https://www.ncbi.nlm.nih.gov/pubmed/35468729
http://dx.doi.org/10.1186/s10194-022-01419-7

Ejemplares similares